Prostaglandin analogues get the job done

Article

Travoprost, latanoprost and bimatoprost all significantly reduce intraocular pressure (IOP) and increase ocular perfusion pressure (OPP) in patients with primary open angle glaucoma (POAG) or ocular hypertension (OHT), according to report published online ahead of print in Acta Ophthalmologica Scandinavica.

Travoprost, latanoprost and bimatoprost all significantly reduce intraocular pressure (IOP) and increase ocular perfusion pressure (OPP) in patients with primary open angle glaucoma (POAG) or ocular hypertension (OHT), according to report published online ahead of print in Acta Ophthalmologica Scandinavica.

Gurbuz Koz and colleagues from the Ankara Numube Education and Research Hospital, Ankara, Turkey enrolled 60 newly diagnosed patients and randomly assigned them to receive either travoprost 0.004% (n=12 with POAG, n=8 with OHT), latanoprost 0.005% (n=11 with POAG, n=9 with OHT) or bimatoprost 0.03% (n=13 with POAG, n=7 with OHT).

At six-months follow-up, IOP had decreased from 26.4±3.3 mmHg to 20.9±1.9 mmHg in the travoprost group, from 26.8±1.3 mmHg to 20.8±2.4 mmHg in the latanoprost group and from 25.8±1.8 mmHg to18.3±1.2 mmHg in the bimatoprost group. A significant increase in OPP was also seen in each group.

The authors of this study concluded that all three prostaglandin analogues are equally efficacious at reducing IOP and increasing OPP in POAG patients.

Related Videos
ARVO 2024: Andrew D. Pucker, OD, PhD on measuring meibomian gland morphology with increased accuracy
 Allen Ho, MD, presented a paper on the 12 month results of a mutation agnostic optogenetic programme for patients with severe vision loss from retinitis pigmentosa
Noel Brennan, MScOptom, PhD, a clinical research fellow at Johnson and Johnson
ARVO 2024: President-elect SriniVas Sadda, MD, speaks with David Hutton of Ophthalmology Times
Elias Kahan, MD, a clinical research fellow and incoming PGY1 resident at NYU
Neda Gioia, OD, sat down to discuss a poster from this year's ARVO meeting held in Seattle, Washington
Eric Donnenfeld, MD, a corneal, cataract and refractive surgeon at Ophthalmic Consultants of Connecticut, discusses his ARVO presentation with Ophthalmology Times
John D Sheppard, MD, MSc, FACs, speaks with David Hutton of Ophthalmology Times
Paul Kayne, PhD, on assessing melanocortin receptors in the ocular space
Osamah Saeedi, MD, MS, at ARVO 2024
© 2024 MJH Life Sciences

All rights reserved.